SuperworthMoleculin Biotech EPS MBRX
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Dec 31, 2021
- −$4500.00
- Latest quarter, Q4 FY21
- −$750.00
- Fiscal year 2021
- −$4500.00
Moleculin Biotech's earnings per share was −$4500.00 over the twelve months to Dec 31, 2021.
In its latest quarter, Q4 FY21, it was −$750.00.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2021 | −$4500.00 | n/a |
| FY2020 | −$13050.00 | n/a |
| FY2019 | −$15300.00 | n/a |
| FY2018 | −$20700.00 | n/a |
| FY2017 | −$22500.00 | n/a |
| FY2016 | −$16650.00 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q4 FY21 | −$750.00 | n/a | −$4500.00 | |
| Q3 FY21 | −$1125.00 | n/a | −$5550.00 | |
| Q2 FY21 | −$1125.00 | n/a | −$6900.00 | |
| Q1 FY21 | −$1500.00 | n/a | −$13425.00 | |
| Q4 FY20 | −$1800.00 | n/a | −$13050.00 | |
| Q3 FY20 | −$2475.00 | n/a | −$14850.00 | |
| Q2 FY20 | −$7650.00 | n/a | −$16425.00 | |
| Q1 FY20 | −$1125.00 | n/a | −$10125.00 | |
| Q4 FY19 | −$3600.00 | n/a | −$15300.00 | |
| Q3 FY19 | −$4050.00 | n/a | −$16200.00 | |
| Q2 FY19 | −$1350.00 | n/a | −$15750.00 | |
| Q1 FY19 | −$6300.00 | n/a | −$23400.00 |
Against its peers
Companies in Healthcare nearest Moleculin Biotech's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| MBRXMoleculin Biotech | n/m | |
| NEPHNephros | $0.16 | +33% a year |
| ATNMActinium Pharmaceuticals | $0.36 | |
| APTAlpha Pro Tech | $0.41 | +24% a year |
| Peer median | $0.36 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Moleculin Biotech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.